Clinical controversies in the management of critically ill patients with severe sepsis: Resuscitation fluids and glucose control

Virulence

Volumn 5, Issue 1, 2014, Pages

  Finfer, Simon ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Albumin; Fluid therapy; Glucose control; Hetastarch; Insulin; Normal saline; Outcome; Severe sepsis; Stress hyperglycemia

Indexed keywords

ALBUMIN; AMYLASE; CORTICOSTEROID; GLUCOSE; HETASTARCH; HYDROCORTISONE; RINGER LACTATE SOLUTION; ALBUMINOID; HETASTARCH DERIVATIVE; INSULIN; ISOTONIC SOLUTION; SODIUM CHLORIDE;

ARTIFICIAL VENTILATION; BACTEREMIA; CENTRAL VENOUS PRESSURE; CRITICALLY ILL PATIENT; CRYSTALLOID; DIABETES MELLITUS; FLUID RESUSCITATION; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; INTENSIVE CARE; MEAN ARTERIAL PRESSURE; META ANALYSIS (TOPIC); MORTALITY; OXYGEN SATURATION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; SEPTIC SHOCK; URINE VOLUME; CRITICAL ILLNESS; FLUID THERAPY; GLUCOSE BLOOD LEVEL; GLUCOSE CONTROL; METHODOLOGY; MULTIPLE ORGAN FAILURE; OUTCOME; PATHOPHYSIOLOGY; RESUSCITATION; SEVERE SEPSIS; STRESS HYPERGLYCEMIA;

ALBUMIN; FLUID THERAPY; GLUCOSE CONTROL; HETASTARCH; INSULIN; NORMAL SALINE; OUTCOME; SEVERE SEPSIS; STRESS HYPERGLYCEMIA;

ALBUMINS; BLOOD GLUCOSE; CRITICAL ILLNESS; FLUID THERAPY; GLUCOSE; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; HYPERGLYCEMIA; INSULIN; INTENSIVE CARE; ISOTONIC SOLUTIONS; MULTIPLE ORGAN FAILURE; RESUSCITATION; SEPSIS;

EID: 84891649181     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.25855     Document Type: Review

References (48)

1. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30:536-555. PMID:1499729; http://dx.doi.org/10.1007/s00134-004-2210-z
2. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al.; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. [comment]. N Engl J Med 2001; 345:1368-1377. PMID:11794169; http://dx.doi.org/10.1056/NEJMoa010307
3. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247-2256. PMID:15163774; http://dx.doi.org/10.1056/NEJMoa040232
4. Cook D. Is albumin safe? N Engl J Med 2004; 350:2294-2296. PMID:15163781; http://dx.doi. org/10.1056/NEJMe048095
5. Finfer S, McEvoy S, Bellomo R, McArthur C, Myburgh J, Norton R; SAFE Study Investigators. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med 2011; 37:86-96. PMID:20924555; http://dx.doi. org/10.1007/s00134-010-2039-6
6. Delaney AP, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med 2011; 39:386-391. PMID:21248514; http://dx.doi. org/10.1097/CCM.0b013e3181ffe217
7. Akech S, Gwer S, Idro R, Fegan G, Eziefula AC, Newton CR, et al. Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial. PLoS Clin Trials 2006; 1:e21. PMID:16998584; http://dx.doi.org/10.1371/journal.pctr.0010021
8. Maitland K, Pamba A, English M, Peshu N, Marsh K, Newton C, et al. Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. Clin Infect Dis 2005; 40:538-545. PMID:15712076; http://dx.doi.org/10.1086/427505s011
9. Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, et al.; FEAST Trial Group. Mortality after fluid bolus in African children with severe infection. N Engl J Med 2011; 364:2483-2495. PMID:21615299; http://dx.doi.org/10.1056/NEJMoa1101549
10. Maitland K, George EC, Evans JA, Kiguli S, Olupot-Olupot P, Akech SO, et al.; FEAST trial group. Exploring mechanisms of excess mortality with early fluid resuscitation: insights from the FEAST trial. BMC Med 2013; 11:68. PMID:23496872; http://dx.doi.org/10.1186/1741-7015-11-68
11. Anon. Early Albumin Resuscitation During Septic Shock. http://www clinicaltrials gov/ct2/show/NCT00327704?term=NCT00327704&rank=1 2011
12. Anon. Volume Replacement With Albumin in Severe Sepsis (ALBIOS). http://www clinicaltrials gov/ct2/show/NCT00707122
13. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34:17-60. PMID:18058085; http://dx.doi. org/10.1007/s00134-007-0934-2
14. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al.; German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125-39. PMID:18184958; http://dx.doi. org/10.1056/NEJMoa070716
15. Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, et al.; SAFE TRIPS Investigators. Resuscitation fluid use in critically ill adults: an international crosssectional study in 391 intensive care units. Crit Care 2010; 14:R185. PMID:20950434; http://dx.doi. org/10.1186/cc9293
16. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2010; CD007594. PMID:20091640
17. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, et al.; 6S Trial Group; Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367:124-34. PMID:22738085; http://dx.doi.org/10.1056/NEJMoa1204242
18. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al.; CHEST Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367:1901-1911. PMID:23075127; http://dx.doi.org/10.1056/ NEJMoa1209759
19. Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S; CHEST Management Committee. Fluid resuscitation with 6 % hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 2013; 39:558-68. PMID:23407978; http://dx.doi.org/10.1007/s00134- 013-2840-0
20. Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and metaanalysis. JAMA 2013; 309:678-88. PMID:23423413; http://dx.doi.org/10.1001/jama.2013.430
21. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, et al. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 2013; 346:f839. PMID:23418281; http://dx.doi.org/10.1136/bmj.f839
22. Patel A, Waheed U, Brett SJ. Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis. Intensive Care Med 2013; 39:811-822. PMID:23430019; http://dx.doi.org/10.1007/s00134-013-2863-6
23. Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. Crit Care 2012; 16:R94. PMID:22624531; http://dx.doi.org/10.1186/cc11358
24. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al.; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39:165-228. PMID:23361625; http://dx.doi.org/10.1007/s00134-012-2769-8
25. Morgan TJ, Venkatesh B, Hall J. Crystalloid strong ion difference determines metabolic acid-base change during acute normovolaemic haemodilution. Intensive Care Med 2004; 30:1432-1437. PMID:14991093; http://dx.doi.org/10.1007/s00134-004-2176-x
26. Guidet B, Soni N, Della Rocca G, Kozek S, Vallet B, Annane D, et al. A balanced view of balanced solutions. Crit Care 2010; 14:325. PMID:21067552; http://dx.doi.org/10.1186/cc9230
27. Shaw AD, Bagshaw SM, Goldstein SL, Scherer LA, Duan M, Schermer CR, et al. Major complications, mortality, and resource utilization after open abdominal surgery: 0.9% saline compared to Plasma-Lyte. Ann Surg 2012; 255:821-829. PMID:22470070; http://dx.doi.org/10.1097/SLA.0b013e31825074f5
28. Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 2012; 308:1566-1572. PMID:23073953; http://dx.doi. org/10.1001/jama.2012.13356
29. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med 2006; 355:1903-1911. PMID:17079764; http://dx.doi. org/10.1056/NEJMcp060094
30. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003; 78:1471-1478. PMID:14661676; http://dx.doi. org/10.4065/78.12.1471
31. Williams LS, Rotich J, Qi R, Fineberg N, Espay A, Bruno A, et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 2002; 59:67-71. PMID:12105309; http://dx.doi.org/10.1212/WNL.59.1.67
32. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001; 32:2426-2432. PMID:11588337; http://dx.doi.org/10.1161/hs1001.096194
33. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355:773-778. PMID:10711923; http://dx.doi.org/10.1016/S0140-6736(99)08415-9
34. NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1346-9. PMID:19318385
35. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359-1367. PMID:11794168; http://dx.doi.org/10.1056/NEJMoa011300
36. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449-461. PMID:16452557; http://dx.doi. org/10.1056/NEJMoa052521
37. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26:57-65. PMID:7797776; http://dx.doi.org/10.1016/0735-1097(95)00126-K
38. Bellomo R, Egi M. Glycemic control in the intensive care unit: why we should wait for NICE-SUGAR. Mayo Clin Proc 2005; 80:1546-1548. PMID:16342646; http://dx.doi.org/10.4065/80.12.1546
39. Annane D, Cariou A, Maxime V, Azoulay E, D'honneur G, Timsit JF, et al.; COIITSS Study Investigators. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010; 303:341-348. PMID:20103758; http:// dx.doi.org/10.1001/jama.2010.2
40. Arabi YM, Dabbagh OC, Tamim HM, Al-Shimemeri AA, Memish ZA, Haddad SH, et al. Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. Crit Care Med 2008; 36:3190-3197. PMID:18936702; http:// dx.doi.org/10.1097/CCM.0b013e31818f21aa 41.
41. De La Rosa GdelC, Donado JH, Restrepo AH, Quintero AM, González LG, Saldarriaga NE, et al.; Grupo de Investigacion en Cuidado intensivo: GICIHPTU. Strict glycemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial. Crit Care 2008; 12:R120. PMID:18799004; http://dx.doi.org/10.1186/cc7017
42. Preiser JC, Devos P, Ruiz-Santana S, Mélot C, Annane D, Groeneveld J, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 2009; 35:1738-1748. PMID:19636533; http://dx.doi.org/10.1007/s00134-009-1585-2
43. Finfer S, Liu B, Chittock DR, Norton R, Myburgh JA, McArthur C, et al.; NICE-SUGAR Study Investigators. Hypoglycemia and risk of death in critically ill patients. N Engl J Med 2012; 367:1108-18. PMID:22992074; http://dx.doi.org/10.1056/NEJMoa1204942
44. Egi M, Bellomo R, Stachowski E, French CJ, Hart GK, Taori G, et al. Hypoglycemia and outcome in critically ill patients. Mayo Clin Proc 2010; 85:217-224. PMID:20176928; http://dx.doi.org/10.4065/mcp.2009.0394
45. Yu WK, Li WQ, Wang XD, Yan XW, Qi XP, Li N, et al. [Influence and mechanism of a tight control of blood glucose by intensive insulin therapy on human sepsis]. Zhonghua Wai Ke Za Zhi 2005; 43:29-32. PMID:15774170
46. Savioli M, Cugno M, Polli F, Taccone P, Bellani G, Spanu P, et al. Tight glycemic control may favor fibrinolysis in patients with sepsis. Crit Care Med 2009; 37:424-431. PMID:19114908; http://dx.doi.org/10.1097/CCM.0b013e31819542da
47. Kansagara D, Fu R, Freeman M, Wolf F, Helfand M. Intensive insulin therapy in hospitalized patients: a systematic review. Ann Intern Med 2011; 154:268-282. PMID:21320942; http://dx.doi.org/10.7326/0003- 4819-154-4-201102150-00008
48. American Diabetes Association. Standards of medical care in diabetes--2012. Diabetes Care 2012; 35(Suppl 1):S11-S63. PMID:22187469; http://dx.doi. org/10.2337/dc12-s011